Replies to post #370409 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

It was identified in the first KEM analysis. Then it was specified as a testing point in a subsequent trial.

Number of participants with pre-specified genetic variants [ Time Frame: 48 weeks ]
AD relevant pre-specified genetic variants will be assessed. Statistical testing of treatment differences within subgroups will be performed

The above is from the current AD trial, the other outcomes section.
Read the KEM analysis of the P2a trial for the discussion.

And you might mention the next sentence to the part you quoted.

Recently the company has dropped any references to that as a PM with Missling saying recently that all types of APOE respond at the high dose level.